Vincerx Pharma (VINC)
(Delayed Data from NSDQ)
$0.65 USD
-0.03 (-4.43%)
Updated Jul 29, 2024 03:59 PM ET
After-Market: $0.64 -0.01 (-1.52%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum D VGM
Price, Consensus and EPS Surprise
VINC 0.65 -0.03(-4.43%)
Will VINC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VINC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VINC
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
VINC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VINC
12 Health Care Stocks Moving In Thursday's After-Market Session
Analysts Conflicted on These Healthcare Names: Cerevel Therapeutics Holdings (CERE), Cullinan Management (CGEM) and Vincerx Pharma Inc (VINC)
Vincerx Pharma GAAP EPS of -$0.58
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
VINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024